您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > ANT-3310 sodium
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ANT-3310 sodium
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ANT-3310 sodium图片
CAS NO:2410688-61-6
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍
ANT-3310 sodium (ANT3310) is a novel and covalent Serine β-Lactamase inhibitor of the diazabicyclooctane class with a broad-spectrum of antibacterial activity. It uses a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs, and inhibits serine β-Lactamase with IC50 values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). ANT-3310 sodium also potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB).
理化性质和储存条件

Molecular Formula: C6H8FN2NaO5S;

Molecular Weight: 262.19

Synonym: ANT-3310; ANT 3310; ANT3310; ANT-3310 sodium;

Chemical Name: sodium (2R,5R)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate

InChi Key: UIJIKXQAJBMNIR-JBUOLDKXSA-M

InChi Code: InChI=1S/C6H9FN2O5S.Na/c7-5-2-1-4-3-8(5)6(10)9(4)14-15(11,12)13;/h4-5H,1-3H2,(H,11,12,13);/q;+1/p-1/t4-,5+;/m1./s1

SMILES Code: O=C(N1[C@@H](CC[C@@H]2C1)F)N2OS(=O)(O[Na])=O


    In VitroANT-3310 sodium (Compound 21, 0.006 to 3 000 nM, 10 min) inhibits a series of Serine β-Lactamase (AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2), with IC<>50 values ranging from 1 nM to 175 nM[1]. ANT3310 sodium shows a low in vitro cytotoxicity (IC<>50:> 100 μM) in HepG2 cell, cardiotoxicity (inhibition of the hERG potassium ion channel), and genotoxicity (Ames test)[1].
    In VivoANT-3310 sodium (intravenous injection, 25-100 mg/kg, at 1, 3, 5, and 7 h postinfection) reduces bacterial burdens in murine thigh infection model[1]. ANT3310 sodium (intravenous injection, 1 mg/kg, Male Swiss albino mice) shows a T1/2 value of 0.64 h, AUC value of 412 ngoh/mL, and Cl value of 40 mL/min/kg (pharmacokinetic assay)[1]. Animal Model: Murine thigh infection model[1] Dosage: 25, 50, and 100 mg/kg Administration: Intravenous injection, at 1, 3, 5, and 7 h postinfection Result: Reduced bacterial burdens (colony forming units, CFU) in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM.